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Abstract
Recently, we created a family of engineered G protein-coupled receptors (GPCRs) called DREADD (designer receptors 
exclusively activated by designer drugs) which can precisely control three major GPCR signaling pathways (Gq, Gi, and Gs). 
DREADD technology has been successfully applied in a variety of in vivo studies to control GPCR signaling, and here we 
describe recent advances of DREADD technology and discuss its potential application in drug discovery, gene therapy, and 
tissue engineering.
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Introduction
G protein-coupled receptors (GPCRs) represent the larg-
est family of membranous signaling molecules and are 
characterized structurally by a highly conserved seven-
transmembrane domain motif (Allen and Roth, 2011; 
Meltzer and Roth, 2013). GPCRs recognize an incredible 
variety of ligands, including odorants, photons, neuro-
transmitters, lipids, hormones, peptides, and other small 
molecules, and regulate intracellular response to adapt 
to the ever-changing environment (Allen and Roth, 2011). 
Upon agonist activation, GPCRs undergo prototypical 
structural re-arrangements facilitating the interaction 
with a family of canonical heterotrimeric G-proteins 
(e.g., Gq, Gs, Gi, and G12/13) and G protein-independent 
signaling molecules (Allen and Roth, 2011). GPCR sign-
aling modulates virtually every known physiological 
response (Allen and Roth, 2011)
To control GPCR signaling for neuropsychopharmaco-
logical therapeutics, “selective” agonists or antagonists are 
typically developed (Besnard et al., 2012; Meltzer and Roth, 
2013). However, because most neuronal cells express multi-
ple GPCRs and because most GPCRs are expressed in multi-
ple tissues (Regard et  al., 2008), it is essentially impossible 
to regulate a specific GPCR-signaling pathway in a selective 
cell population by known pharmacological approaches. 
Additionally, the presence of endogenous receptor ligands 
and the lack of true specificity of pharmacological probes 
for GPCRs further confound the neuropsychopharmacologi-
cal approach. To overcome these inherent problems asso-
ciated with GPCR therapeutic approaches, the past two 
decades have seen a number of chemical-genetic approaches 
designed to control GPCR signaling in vivo (see Sternson and 
Roth, 2014, for recent review). Although the ‘first generation’ 
chemogenetic tools were useful from a heuristic perspective, 
they were not widely adapted (see Sternson and Roth, 2014, 
for review).
DREADD: A Useful and Robust 
Chemogenetic Platform
We adopted a novel strategy to discover useful chemogenetic 
tools utilizing directed molecular evolution in yeast. We were able 
to eventually evolve human muscarinic receptors to be activated 
by nM concentrations of the pharmacologically inert clozapine 
metabolite clozapine-N-oxide (CNO) and to simultaneously be 
insensitive to the native ligand acetylcholine (Armbruster et al., 
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2007). Importantly, the engineered receptors which we dubbed 
DREADDs (Designer Receptors Exclusively Activated by Designer 
Drugs) had minimal constitutive activity in vitro (Armbruster 
et al., 2007) and in vivo, even when expressed at high levels in 
neurons (Alexander et al., 2009; Zhu et al., 2014).
Since the initial description of DREADD technology 
(Armbruster et  al., 2007), three DREADDs have been mostly 
commonly used in the neurosciences: hM3Dq, which is cou-
pled to Gαq signaling and induces firing of neurons (Alexander 
et  al., 2009); hM4Di, which is coupled to Gαi signaling and 
mediates neuronal (Armbruster et  al., 2007) and synaptic 
silencing (Stachniak et  al., 2014); and rM3Ds, which is cou-
pled to Gαs signaling and which modulates neuronal activity 
(Farrell et al., 2013).
A schematic diagram for the application of DREADD technol-
ogy is shown in Figure 1. The typical strategy for using DREADD 
technology to gain remote control over neuronal signaling is 
quite simple and is as follows (see Figure 1 for diagram of ways 
of expressing DREADDs):
•	 Express the DREADD in the cell-type of interest via either 
transgenic or viral technology
•	  For virally-mediated transduction wait 2–3 weeks for 
expression
•	 Administer CNO either via parenteral or oral administra-
tion
Figure 1. Schematic diagram for the application of DREADD technology in vivo. (A) Two types of DREADD transgenic mouse models have been developed: cre-dependent 
and tet-dependent. DREADDs can be expressed in genetically defined cell populations after crossing with cre- or tet-off driver mouse lines. (B) Two types of DREADDs 
viruses were developed: cre-dependent and cre-independent. In the cre-dependent system, virus containing double-floxed inverted DREADDs are microinfused into 
the appropriate brain region in mice which express cell-type specific Cre drivers. DREADDs are flipped into the correct orientation and expressed after cre-mediated 
recombination to achieve very precise cell-type specific expression.
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•	 Within a few minutes of CNO administration, the effect due 
to activation (via hM3Dq), inhibition (via hM4Di), or modula-
tion (via GsD) of neuronal signaling occurs
•	 Monitor behavior and/or neuronal firing in freely-moving 
animals
•	 The effects of CNO will be negligible in animals which do 
not express DREADDs and profound in animals expressing 
DREADDs
Widespread Adoption of DREADD 
Technology
DREADDs have been successfully demonstrated to control 
individual GPCR signaling in many in vivo studies from yeast, 
drosophila, mice, rats, and—perhaps in the near future—pri-
mates (Farrell and Roth, 2012) and, as of August 2014, more 
than 500 publications have cited DREADD technology. In the 
Table 1. Summary of Toolkit of DREADDs Technology
Expression system Subtype of DREADDs Vector information Control system Source Publication






Cre-LoxP Roth’s lab  
(In validation)
RIPII-hM3Dq Insulin promoter II Wess’s lab Guettier et al. (2009)
C-fos-hM3Dq C-fos promoter Mayford’s lab Garner et al. (2012)









Cre-LoxP and  
FLP-FRT
Dymecki’s lab Ray et al. (2011)
rM3Ds Adora2A-rM3Ds Adora2A promoter Available at Jackson 
Labs
Farrell et al. (2013)
RIPII-rM3Ds Insulin promoter II Wess’s lab Guettier et al. (2009)
AAV virus hM3Dq HA-hM3Dq-IRES- 
mCitrine
hSyn, CaMKIIa,  
GFAP promoter
UNC Viral Vector Core; 




hSyn, CaMKIIa,  
GFAP promoter
UNC Viral Vector Core; 




Cre-LoxP UNC Viral Vector Core; 
plasmids available via 
ADDGENE




hSyn, CaMKIIa,  
GFAP promoter
UNC Viral Vector Core; 




hSyn, CaMKIIa,  
GFAP promoter
UNC Viral Vector Core; 





Cre-LoxP UNC Viral Vector Core; 




CaMKIIa, GFAP  
promoter
UNC Viral Vector Core; 




Cre-LoxP UNC Viral Vector Core; 
plasmids available via 
ADDGENE




Cre-LoxP Available directly from 
Roth lab




Cre-LoxP Available directly from 
Roth lab
HSV virus hM4Di ENK-hM4Di Enk promoter Unknown availability Ferguson et al. (2011)
DYN-hM4Di Dyn promoter Unknown availability Ferguson et al. (2011)
CAV2 virus hM3Dq hSyn-DIO-rM3Ds- 
mCherry
Cre-LoxP Unknown availability Boender et al. (2014)
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central nervous system (CNS), DREADDs have been shown to 
control neuronal activities in a variety of neurons, including 
glutamatergic (Alexander et al., 2009; Zhu et al., 2014), sero-
tonergic (Ray et  al., 2011), dopaminergic (Dell’Anno et  al., 
2014), and GABAergic neurons (Kong et  al., 2012), to name 
but a few. DREADDs have also been used to control glial cell 
activity to modulate the autonomic nervous system (Agulhon 
et al., 2013). In periphery, DREADDs have been used to control 
GPCR signaling in pancreatic beta-cells (Guettier et al., 2009), 
hepatocytes (Li et al., 2013), and breast cancer cells (Yagi et al., 
2011). As these applications have been reviewed recently we 
will not comment on them further here (Urban and Roth, in 
press).
Recent Advances in the DREADD Toolkit and 
DREADD Resources
Currently, a substantial collection of DREADD-based tools is 
available to control GPCR signaling in vivo (see Table  1). Three 
DREADD transgenic mouse lines created by the Roth lab can 
now be obtained from Jackson Labs (Table  1). Cre-dependent 
hM3Dq and hM4Di transgenic mice are in the process of vali-
dation in the Roth lab and will be made available soon to pro-
vide cell-type specific transgenic control of DREADD expression 
as outlined in Figure  1. Tissue-specific and cell type–specific 
expression of DREADDs can also be achieved by viral deliv-
ery (Krashes et  al., 2011; Urban and Roth, in press). For many 
uses viral delivery is time-saving and yields a more precisely 
controlled DREADD expression. A variety of viral vectors—Cre-
dependent or -independent—are listed in Table 1 and the major-
ity of them can be obtained from UNC viral core facility (http://
www.med.unc.edu/genetherapy/vectorcore/research-grade/ 
in-stock-aav-vectors/roth). Current DREADD-based plasmids are 
available from ADDGENE (http://www.addgene.org/Bryan_Roth/) 
and as a service to DREADD users a blog is updated frequently 
(http://chemogenetic.blogspot.com/).
We continue to develop new chemogenetic tools and soon 
will be describing those which afford bidirectional control of 
GPCR signaling in same-cell population via different synthetic 
ligands. In the meantime, new derivatives of DREADDs have 
been developed by others which are likely to be quite useful. 
Thus, for example, an arrestin-biased DREADD was generated 
(Nakajima and Wess, 2012) and an axonal selective hM4D-neu-
rexin variant was developed as a presynaptic silencer (Stachniak 
et al., 2014).
Future Directions for DREADD Technology
The GPCR superfamily continues to be one of the major targets 
for drug discovery, although CNS drug discovery remains slow 
and risky (Meltzer and Roth, 2013). Indeed, less than 5% of CNS 
drugs entering Phase I  clinical trials are eventually approved 
by the FDA, and many GPCR-targeted drugs fail in Phase II and 
III clinical trials due to lack of clinical efficiency (Bradley et al., 
2014). This raises the questions as to whether current animal 
models really recapitulate the physiological/pathological condi-
tion seen in human disease and whether pharmacological inter-
vention of disease-related GPCR targets can ultimately deliver 
the desired therapeutic response. We suggest that DREADDs 
may represent a new “pre-evaluation” approach for GPCR drug 
discovery. For example, we can pre-evaluate whether pharma-
cological intervention of a given GPCR-signaling process by 
DREADD achieves the desired therapeutic response before start-
ing a long and costly drug discovery process (Figure 2).
DREADDs may also represent a novel approach for combining 
gene therapy, tissue engineering, and synthetic biology. Indeed, 
Figure 2. DREADDs represent a chemogenetic tool to modulate GPCR signaling in vivo. (A) Introducing two mutations in transmenbrane III and V of muscarinic receptors 
which create DREADDs receptors that can precisely control the Gq-, Gi-, or Gs-signaling pathways. (B) DREADDs technology has been successfully applied in β-cells, astrocytes, 
and a variety of neurons to control GPCR signaling in vivo. (C) DREADDs technology has a great potential to be used in drug discovery, gene therapy, and tissue engineering.
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in an important recent study Dell’Anno et al. (2014) demonstrated 
robust and bidirectional remote control of DREADD-expressing 
dopaminergic neurons, which induced from iPSCs (Induced 
pluripotent stem cells), and were able to markedly enhance the 
beneficial effects in a mouse model of Parkinson’s Disease. This 
represents the first demonstration of combining DREADD tech-
nology, gene therapy, and tissue engineering. Theoretically this 
approach could be potentiated by CRISPR (clustered regularly 
interspaced short palindromic repeats) technology (Hsu et  al., 
2014). Thus, for instance, one could envision engineering iPSCs 
by knocking in DREADDs into the downstream regions of dis-
ease-related GPCR targets using CRISPR. DREADDs could then be 
expressed at physiologically relevant levels in the correct cellular 
context. Following transplantation, we could then remotely con-
trol engineered iPSCs by administrating CNO, a drug-like small 
molecule, to potentially cure human disease.
Other applications are equally obvious—e.g., by engineering 
endogenous muscarinic receptors via CRISPR technology one 
could create mice in which endogenous muscarinic receptors 
are replaced by DREADDs to achieve precise control over mus-
carinic receptor subtype signaling. This would allow research-
ers to deconstruct the roles of various muscarinic receptors in 
neuropsychiatric disease models. Alternatively, CRISPR-based 
technology could be used to knock-in DREADDs into essen-
tially any locus in the genome to achieve cell-type specific con-
trol of signaling in virtually any tissue and organ. Indeed, with 
the currently available tissue engineering, gene therapy, and 
synthetic biology tools we are limited only by our imagination 
in how we might adapt DREADD technology for interrogating 
and ultimately treating human neuropsychiatric diseases.
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